Why have Mepolizumab therapy done in China specifically?

China offers the same FDA- and EMA-approved mepolizumab (branded as Nucala) at a significantly lower cost—approximately $8,500 per year versus $35,000–$50,000 in the U.S. or Europe. Major pulmonary centers in Beijing, Shanghai, and Guangzhou have extensive experience with biologic therapies, high-volume patient cohorts, and adherence to international treatment protocols. Additionally, combined medical travel packages often include coordination with English-speaking specialists and follow-up telemedicine.